Boston, Massachusetts-based Imara Inc. is slated to debut on the Nasdaq Global Select Market, under the symbol 'IMRA', on March 12, 2020.
Imara is a clinical-stage biopharmaceutical company developing novel therapeutics to treat patients with rare inherited genetic disorders of hemoglobin, known as...